---
title: "TRANSTHERA has completed the first patient dosing in the Phase III clinical study of Engeletinib"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283254943.md"
description: "TRANSTHERA-B announced that the company's core product Tinengotinib (TT-00420) has completed the first patient dosing in a confirmatory Phase III clinical study for the treatment of advanced cholangiocarcinoma. Tinengotinib is an innovative multi-target small molecule kinase inhibitor developed in-house and is currently in the new drug application stage, exerting anti-tumor effects by targeting tumor cells and improving the tumor microenvironment"
datetime: "2026-04-19T13:00:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283254943.md)
  - [en](https://longbridge.com/en/news/283254943.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283254943.md)
---

# TRANSTHERA has completed the first patient dosing in the Phase III clinical study of Engeletinib

TRANSTHERA-B (02617.HK) announced that the company's core product Tinengotinib (TT-00420) has completed the first patient dosing in a confirmatory Phase III clinical study for the treatment of advanced cholangiocarcinoma.

Tinengotinib is an innovative multi-target small molecule kinase inhibitor developed independently and is currently in the new drug application stage, exerting anti-tumor effects by targeting tumor cells and improving the tumor microenvironment

### Related Stocks

- [02617.HK](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

- [InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE](https://longbridge.com/en/news/284467442.md)
- [TransThera Raises HK$282 Million via H-Share Placing to Fund Cancer Drug Push](https://longbridge.com/en/news/283489861.md)
- [Ventra Provides Update On TT Property](https://longbridge.com/en/news/284572378.md)
- [12:14 ETImmune Cells Rewire Themselves to Keep Battling Tumors in Nutrient Poor Environments](https://longbridge.com/en/news/284611566.md)
- [Sapient Launches Tumor Protein Mapping Platform to Characterize Functional Biology Across Critical Dimensions in Human Tumors](https://longbridge.com/en/news/284403125.md)